Glyco-biomarker CA19-9 Detection Service

Glyco-biomarker CA19-9 Detection Service

The glycan carbohydrate antigen 19-9 (CA19-9), also known as sialic acid-LewisA, plays a crucial role in the process of intercellular recognition. Due to the high sensitivity and specificity of CA19-9 for pancreatic cancer, CD BioGlyco provides glyco-biomarker CA19-9 detection service through various methods to help researchers explore new therapies for pancreatic cancer.


Pancreatic ductal adenocarcinoma is the leading cause of cancer-related death and has the lowest survival rate of any solid cancer. The discovery of biomarkers for early detection of pancreatic cancer is an urgent need to improve survival, although studies evaluating biomarkers for early detection are rarely performed using samples from patients with the preclinical disease. It has been reported that CA19-9 is one of the most important and widely used glyco-biomarkers for pancreatic cancer.

CA19-9 can be used as an adjuvant diagnostic indicator for pancreatic cancer, gallbladder cancer and other malignancies. This antigen exists in the pancreatic, gallbladder, liver and intestinal tissues of embryonic fetuses, and the content in normal human tissues is very low. In the serum of patients with malignant tumors of the digestive tract, especially pancreatic cancer and gallbladder cancer, the content of CA 19-9 is significantly increased. But it is mainly used as an indicator for disease monitoring and predicting recurrence rather than early diagnosis. In addition, CA19-9 is useful for the differential diagnosis of gastrointestinal diseases (e.g. pancreatic cancer and pancreatitis, gastric cancer and gastric ulcer).

Illustration of  the preparation process for MGNRsCA19‑9, MGNRsMUC1, colorimetric immunosensor, and  the detection procedures of CA19-9 and MUC1 based on the decolorization of MO  by MGNRs in the presence of NaBH4. Fig.1 Illustration of the preparation process for MGNRsCA19‑9, MGNRsMUC1, colorimetric immunosensor, and the detection procedures of CA19-9 and MUC1 based on the decolorization of MO by MGNRs in the presence of NaBH4. (Li, 2019)

Our Strategies

CD BioGlyco offers multiple methods for detecting CA 19-9 in associated body fluids in small quantities for cancer diagnosis. The methods we provide include but are not limited to:

  • We have established a method for the detection of CA 19-9 by protein microarrays based on NIR plasmonic gold nanostructures, which allows nanoscale control of the plasma substrate structure by colloidal lithography, achieving increased sensitivity and tunability of sensitivity.
  • We have developed a facile method for enzyme-free colorimetric immunosensor based on magnetic iron oxide coated gold nanorods (MGNR) nanocomposites that enable sensitive, cost-effective and specific detection of CA19-9 for risk assessment of pancreatic cancer with a small amount of serum without using any enhancing solutions or enzymes.
  • Immunological assays


  • Discovery of therapeutic target in pancreatitis
  • Detecting recurrence of pancreatic cancer
  • Distinguishing between cancer and other diseases of the gland
  • Cancer diagnosis and therapeutic monitoring.

Advantages of Us

  • First-class experimental platform
  • Comprehensive services in the field of glycoproteomics
  • High efficiency and specificity
  • Experiment design according to customer requirements

CD BioGlyco is dedicated to detecting a range of biomarkers including CA19-9 for early cancer diagnosis in small sample sizes, and we offer a wide range of services to meet your research needs. If you are interested in our services, please feel free to contact us.


  1. Li, N.S.; et al. Combined detection of CA19–9 and MUC1 using a colorimetric immunosensor based on magnetic gold nanorods for ultrasensitive risk assessment of pancreatic cancer. ACS Applied Bio Materials. 2019, 2(11):4847-4855.
  2. Jawad, Z.A.; et al. Highly sensitive plasmonic detection of the pancreatic cancer biomarker CA 19-9. Scientific Reports. 2017, 7(1):14309.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.